HTGF et al. back GeneQuine Biotherapeutics

The capital will be used to fund proof-of-concept studies for the company's lead product, GQ-201, a gene therapy drug for the treatment of osteoarthritis in horses. The business is also working on a similar drug for dogs and plans to target human medicine in the long-term.

The GPs said in a statement they saw potential in the product as it met a medical need of a large veterinary market.

Company
GeneQuine started operating in Hamburg in October 2012. The biotech start-up focuses on the development of gene therapy drugs for the treatment of osteoarthritis in horses, dogs and humans.

People
Investment manager Martin Pfister represented HTGF on the deal. Doreen Huhle is investment manager at Innovationsstarter Hamburg.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• Germany
• High-Tech Gründerfonds